Focusing on unmet clinical needs, we collaborate with global innovative companies to efficiently promote clinical development and commercialization of products, and foster transformation of scientific research into clinical practices

R&D Introduction

Focusing on unmet clinical needs, we collaborate with global biotech /biopharma to jointly develop first- or best-in-class* products. To make the most of respective strengths and improve the efficiency of innovative drug research and development, CMS can/will take on responsibility for clinical development and commercialization in China or specific markets.

*Best-in-class: innovative products with the best efficacy, safety or cost-effectiveness in the class due to their innovative formulations or drug delivery systems

~30

Innovative Pipeline Products

>10

Ongoing Clinical Trials, Mostly are Registrational Randomized Controlled Trials (RCTs)

3

NDAs in China

*As at 31 December 2021

R&D Model

01

Equity Investment in Global Biotech and Strategic Collaboration with Global Biopharma

We acquire innovative products that are in the mid- and late-phase of clinical development or have been approved for marketing. CMS is responsible for clinical development, registration and commercialization of products in China and other authorized countries/regions, in order to improve the patient access of innovative medicine.

Read more >>

02

Equity Investment or Strategic Collaboration with Chinese Biotech that Have Innovative Technology Platforms

CMS is responsible for clinical development, registration and commercialization in China and other authorized countries/regions. This allows the biotech companies to focus on drug discovery and preclinical studies, thereby improving R&D efficiency and accelerate the commercialization of domestic innovative products.

Read more >>

03

Customization of Innovative Products

For novel or popular targets in our therapeutic fields of focus, CMS uses CROs to conduct preclinical studies, and manages the entire life cycle of innovative medicines itself, whilst also giving CMS ownership of the product rights globally.

Read more >>

R&D Model

Clinical Development

We have established an in-house clinical development system focused on the four key components: medical, clinical, pharmacovigilance and quality assurance. The process is overseen to provide high-level confidence that the medical strategy is rational, clinical operations are effective and compliant, and product safety risks are controllable.

Proven clinical enrollment capability:
*Tildrakizumab Solution for Injection- Completed enrollment of all the 220 subjects within 2.5 months (including the Chinese Spring Festival holidays)
*Cyclosporine Eye Drops 0.09%- Completed enrollment of all the 384 subjects within 4 months (including the Chinese Spring Festival holidays)
*Methylthioninium Chloride Enteric-coated Sustained-release Tablets- Completed enrollment of all the 1,800 subjects within 6 months (including the Chinese Spring Festival holidays)

临床开发

Pipeline

A broad and differentiated pipeline covering cardio-cerebrovascular, gastroenterology, central nervous system, dermatology and medical aesthetics, ophthalmology, pediatrics, and other specialty fields.

Read more >>

Pipeline